Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-targeting Antibody-drug Conjugate, in Combination with Bevacizumab in Patients with Platinum-Resistant Ovarian Cancer: Maturing Safety and Activity Profile from the FORWARD II Phase 1b Study
IMMUNOGEN IS NOW PART OF ABBVIE
Together we will be working to make a remarkable impact for cancer patients and their communities of care, raising standards of care and advancing a dynamic oncology pipeline.